Zhi-Qiang Ning
Overview
Explore the profile of Zhi-Qiang Ning including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
395
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Xu H, Zhang J, Chen W, Ning Z, Li X
Clin Drug Investig
. 2019 May;
39(6):553-563.
PMID: 31037611
Background And Objectives: Chiglitazar is a novel configuration-restricted non-thiazolidinedione peroxisome proliferator-activated receptor pan-agonist currently in the Phase III clinical development stage for type 2 diabetes mellitus patients. The objective of...
2.
Yi L, Zhang H, Zhang J, You X, Ning Z, Yu J, et al.
Clin Pharmacol Drug Dev
. 2019 Feb;
8(7):934-941.
PMID: 30809967
Chiglitazar (CHI) is a potent and selective peroxisome proliferator-activated receptor potentially for the treatment of patients with type 2 diabetes mellitus (T2DM). An open-label, randomized, 3-period crossover and self-controlled study...
3.
Pan D, Wang W, Liu N, Yang Q, Zhang K, Zhu J, et al.
PPAR Res
. 2017 Oct;
2017:4313561.
PMID: 29056962
Type 2 diabetes mellitus is often treated with insulin-sensitizing drugs called thiazolidinediones (TZD), which improve insulin resistance and glycemic control. Despite their effectiveness in treating diabetes, these drugs provide little...
4.
Zhou Y, Shan S, Li Z, Xin L, Pan D, Yang Q, et al.
Cancer Sci
. 2016 Dec;
108(3):469-477.
PMID: 28004478
Although inhibitors targeting tumor angiogenic pathway have provided improvement for clinical treatment in patients with various solid tumors, the still very limited anti-cancer efficacy and acquired drug resistance demand new...
5.
Ning Z, Lu H, Chen C, Wang L, Cai W, Li Y, et al.
Oncotarget
. 2016 Dec;
8(3):4572-4581.
PMID: 27992364
MicroRNAs (miRNAs) play critical roles in variousbiological processes,including malignancy. Here, we demonstrated that miR-30e levels were markedly reduced in human lung carcinoma specimens in comparisonwith adjacent normal tissues.In addition, miR-30eamounts...
6.
Zhou Y, Pan D, Shan S, Zhu J, Zhang K, Yue X, et al.
Biomed Pharmacother
. 2014 Apr;
68(4):483-91.
PMID: 24721323
Combination of low doses of histone deacetylases inhibitors and chemotherapy drugs is considered as one of the most promising strategies to increase the anticancer efficacy. Chidamide is a novel benzamide...
7.
Dong M, Ning Z, Xing P, Xu J, Cao H, Dou G, et al.
Cancer Chemother Pharmacol
. 2012 Feb;
69(6):1413-22.
PMID: 22362161
Purpose: Chidamide (CS055/HBI-8000) is a new benzamide class of histone deacetylase inhibitor with marked anti-tumor activity. This study reports the phase I results. Methods: Patients with advanced solid tumors or...
8.
Ning Z, Li Z, Newman M, Shan S, Wang X, Pan D, et al.
Cancer Chemother Pharmacol
. 2011 Nov;
69(4):901-9.
PMID: 22080169
Purpose: Chidamide (CS055/HBI-8000) is a new histone deacetylase (HDAC) inhibitor of the benzamide class currently under clinical development in cancer indications. This study reports the in vitro and in vivo...
9.
Liu L, Shan S, Zhang K, Ning Z, Lu X, Cheng Y
Phytother Res
. 2008 Aug;
22(10):1400-3.
PMID: 18690615
The dried, immature fruit of Citrus aurantium L., 'Zhiqiao' in Chinese, has been used to treat cardiovascular diseases in traditional Chinese medicine for centuries. Naringenin and hesperetin and their glycosides...
10.
Li P, Shan S, Chen Y, Ning Z, Sun S, Liu Q, et al.
Br J Pharmacol
. 2006 Jun;
148(5):610-8.
PMID: 16751799
1. The aim of this study was to investigate the capacity of chiglitazar to improve insulin resistance and dyslipidemia in monosodium L-glutamate (MSG) obese rats and to determine whether its...